We

prepared the condensed consolidated financial statements following the

requirements of the Securities and Exchange Commission (SEC) for interim

reporting. As permitted under those rules, certain footnotes or other financial

information that are normally required by accounting principles generally

accepted in the United States of America (U.S. GAAP) can be condensed or

omitted. Balance sheet amounts and operating results for subsidiaries operating

outside the U.S. are as of and for the three-month and six-month periods ended

May 24, 2009, and May 25, 2008. Subsequent events have been evaluated through

August 6, 2009.

We made

certain reclassifications to prior-period amounts to conform to the

second-quarter and six-month 2009 presentations related to the presentation of

noncontrolling interests as a result of adopting a new accounting standard (see

Note 2. Adoption of New

Accounting Policies).

Revenues,

expenses, assets and liabilities can vary during each quarter of the year.

Therefore, the results and trends in these interim financial statements may not

be representative of those for the full year.

We are

responsible for the unaudited financial statements included in this

document. The financial statements include all normal and recurring

adjustments that are considered necessary for the fair presentation of our

financial position and operating results.

The

information included in this Quarterly Report on Form 10-Q should be read in

conjunction with the consolidated financial statements and accompanying notes

included in Pfizer s Annual Report on Form 10-K for the year ended December

31, 2008.

On

January 26, 2009, we announced that we entered into a definitive merger

agreement under which we will acquire Wyeth in a cash-and-stock transaction

valued on that date at $50.19 per share, or a total of $68 billion. While we

have taken actions and incurred costs associated with the pending transaction

that are reflected in our financial statements, the pending acquisition of Wyeth

will not be reflected in our financial statements until consummation. (See Note 14. Pending Acquisition of

Wyeth.)

Included in Other

current liabilities at June 28, 2009 are $1.5 billion of deferred income

taxes.

Note 2. Adoption of New

Accounting Policies

As of

March 30, 2009, we adopted Financial Accounting Standards Board (FASB) Staff

Position (FSP) No. Statement of Financial Accounting Standards (SFAS) 115-2 and

SFAS 124-2, Recognition and

Presentation of Other-Than-Temporary Impairments. FSP SFAS 115-2 and SFAS

124-2 amend the guidance for evaluating and measuring other-than-temporary

impairments for available-for-sale or held-to-maturity debt securities. The

adoption of FSP SFAS 115-2 and SFAS 124-2 did not have a significant impact on

our consolidated financial statements.

As of

March 30, 2009, we adopted FSP No. SFAS 157-4, Determining Fair Value When the

Volume and Level of Activity for the Asset or Liability Have Significantly

Decreased and Identifying Transactions That Are Not Orderly. FSP SFAS

157-4 provides additional guidance for estimating fair value in inactive markets

and the identification of disorderly transactions. FSP SFAS 157-4 was adopted

prospectively and did not have a significant impact on our consolidated

financial statements, but could impact the accounting for acquisitions after

adoption, including our pending acquisition of Wyeth, and other events, balances

and transactions measured at fair value.

As of

January 1, 2009, we adopted SFAS No. 141R, Business Combinations, as

amended. SFAS 141R, as amended, retains the purchase method of accounting for

acquisitions, but requires a number of changes, including changes in the way

assets and liabilities are recognized in purchase accounting. It also changes

the recognition of assets acquired and liabilities assumed arising from

contingencies, requires the capitalization of in-process research and

development costs at fair value and requires the expensing of

acquisition-related costs as incurred. The adoption of SFAS 141R, as amended,

did not impact our consolidated financial statements upon adoption, but will

impact the accounting for acquisitions after adoption, including our pending

acquisition of Wyeth.

PFIZER

INC. AND SUBSIDIARY COMPANIES

NOTES TO

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

As of

January 1, 2009, we adopted FSP No. SFAS 142-3, Determination of the Useful Life of

Intangible Assets. FSP SFAS 142-3 amends the factors considered in

developing renewal or extension assumptions used to determine the useful life of

a recognized intangible asset. Among other things, in the absence of historical

experience, an entity will be required to consider assumptions used by market

participants. The adoption of FSP SFAS 142-3 did not impact our consolidated

financial statements upon adoption, but could impact the accounting for

acquisitions after adoption, including our pending acquisition of

Wyeth.

As of

January 1, 2009, we adopted the provisions of SFAS No. 157, Fair Value Measurements, as

amended, that we did not adopt as of January 1, 2008. SFAS 157, as amended,

defines fair value, expands related disclosure requirements and specifies a

hierarchy of valuation techniques based on the nature of the inputs used to

develop the fair value measures. The adoption of the remaining provisions of

SFAS 157, as amended, did not have a significant impact on our consolidated

financial statements upon adoption, but will impact the accounting for

acquisitions after adoption, including our pending acquisition of Wyeth, and

other events, balances and transactions measured at fair value.

As of

January 1, 2009, we adopted SFAS No. 160, Noncontrolling Interests in

Consolidated Financial Statements, an amendment of Accounting Research

Bulletin No. 51, Consolidated Financial

Statements. SFAS 160 provides guidance for the accounting, reporting and

disclosure of noncontrolling interests, previously referred to as minority

interests. A noncontrolling interest represents the portion of equity (net

assets) in a subsidiary not attributable, directly or indirectly, to a parent.

The adoption of SFAS 160 resulted in a number of changes to the presentation of

our consolidated financial statements, but the amounts associated with

noncontrolling interests are not significant. SFAS 160 could impact our

accounting for acquisitions after adoption, where we do not acquire 100% of the

entity, and our accounting for the deconsolidations of

subsidiaries.

As of

January 1, 2009, we adopted Emerging Issues Task Force (EITF) Issue No. 07-1,

Accounting for Collaborative

Arrangements. EITF 07-1 provides guidance on determining whether an

arrangement constitutes a collaborative arrangement within the scope of the

Issue; how costs incurred and revenue generated on sales to third parties should

be reported in the income statement; how an entity should characterize payments

on the income statement; and what

participants should disclose in the notes to the financial statements about a

collaborative arrangement. The adoption of EITF 07-1 did not have a significant

impact on our consolidated financial statements, and additional disclosures have

been provided. (See Note 4.

Collaborative Arrangements.)

As of

January 1, 2009, we adopted EITF Issue No. 08-3, Accounting by Lessees for

Maintenance Deposits. EITF 08-3 provides guidance that maintenance

deposits paid by a lessee and subsequently refunded only if a lessee fulfills a

maintenance obligation will be accounted for as a deposit asset. The adoption of

EITF 08-3 did not have a significant impact on our consolidated financial

statements.

As of

January 1, 2009, we adopted EITF Issue No. 08-6, Equity Method Investment Accounting

Considerations. EITF 08-6 clarifies how to account for certain

transactions involving equity method investments in areas such as: how to

determine the initial carrying value of the investment; how to allocate the

difference between the investor s carrying value and the investor s share of the

underlying equity of the investment; how to perform an impairment assessment of

underlying intangibles held by the investee; how to account for the investee s

issuance of additional shares; and how to account for an investment on the cost

method when it had been previously accounted for under the equity method. The

adoption of EITF 08-6 did not have a significant impact on our consolidated

financial statements, but could impact the accounting for equity method

investments after adoption.

As of

January 1, 2009, we adopted EITF Issue No. 08-7, Accounting for Defensive Intangible

Assets. EITF 08-7 clarifies the accounting for certain separately

identifiable assets, which an acquirer does not intend to actively use but

intends to hold to prevent its competitors from obtaining access to them. EITF

08-7 requires an acquirer to account for a defensive intangible asset as a

separate unit of accounting, which should be amortized to expense over the

period the asset diminishes in value. The adoption of EITF 08-7 did not have a

significant impact on our consolidated financial statements, but could impact

the accounting for acquisitions after adoption.

Note 3.

Acquisitions

In the

second quarter of 2008, we acquired Encysive Pharmaceuticals Inc. (Encysive), a

biopharmaceutical company whose main asset is Thelin, which is used for the

treatment of pulmonary arterial hypertension. The cost of acquiring Encysive,

through a tender offer and subsequent merger, was approximately

$200 million, including transaction costs. Upon our acquisition of

Encysive, Encysive's change of control repurchase obligations under its

outstanding $130 million 2.5% convertible notes were triggered and, as a result,

Encysive repurchased the convertible notes in consideration for their par value

plus accrued interest in June 2008. In addition, in the second quarter of 2008,

we acquired Serenex, Inc. (Serenex), a privately held biotechnology company,

whose main asset is SNX-5422, an oral Heat Shock Protein 90 (Hsp90) for the

potential treatment of solid tumors and hematological malignancies and an

extensive Hsp90 inhibitor compound library, which has potential uses in treating

cancer, inflammatory and neurodegenerative diseases. In connection with these

acquisitions, through the second quarter of 2008, we recorded $156 million in

Acquisition-related in-process

research and development charges and approximately $450 million in

intangible assets.

PFIZER

INC. AND SUBSIDIARY COMPANIES

NOTES TO

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

In the

first quarter of 2008, we acquired CovX, a privately held biotherapeutics

company specializing in preclinical oncology and metabolic research and the

developer of a biotherapeutics technology platform. Also in the first quarter of

2008, we acquired all the outstanding shares of Coley Pharmaceutical Group,

Inc., (Coley), a biopharmaceutical company specializing in vaccines and drug

candidates designed to fight certain cancers, allergy and asthma disorders, and

autoimmune diseases, for approximately $230 million. In connection with these

and two smaller acquisitions related to Animal Health, we recorded approximately

$398 million in Acquisition-related in-process

research and development charges during the first quarter of 2008. In the second quarter of

2009, we resolved a contingency associated with CovX and recognized $20 million

in Acquisition-related

in-process research and development charges.

Note 4. Collaborative

Arrangements

In the

normal course of business, we enter into collaborative arrangements with respect

to in-line medicines, as well as medicines in development that require

completion of research and regulatory approval. Collaborative arrangements are

contractual agreements with third parties that involve a joint operating

activity, typically a research and/or commercialization effort, where both we

and our partner are active participants in the activity and are exposed to the

significant risks and rewards of the activity. Our rights and obligations under

our collaborative arrangements vary. For example, we have agreements to

co-promote pharmaceutical products discovered by other companies, and we have

agreements where we partner to co-develop and/or participate together in

commercializing, marketing, promoting, manufacturing, and/or distributing a drug

product.

Payments

to or from our collaboration partners are presented in the statement of income

based on the nature of the arrangement (including its contractual terms), the

nature of the payments and applicable accounting guidance. Under co-promotion

agreements, we record the amounts received from our partners as alliance

revenues, a component of Revenues, when our

co-promotion partners are the principal in the transaction and we receive a

share in their net sales or profits. Alliance revenues are recorded when our

co-promotion partners ship the product and title passes to their customer.

Expenses for selling and marketing these products are included in Selling, informational and

administrative expenses. In arrangements where we manufacture a product

for our partner, we record revenues when our partner sells the product and title

passes to their customer. All royalty payments to collaboration partners are

recorded as part of Cost of

sales.

The

amounts and classifications of payments (income/(expense)) between us and our

collaboration partners follow:

Three

Months Ended

Six

Months Ended

(millions

of dollars)

June

28,

2009

June

29,

2008

June

28,

2009

June

29,

2008

Revenues

Revenues(a)

146

126

278

226

Revenues

Alliance revenues (b)

598

563

1,180

1,051

Total

Revenues from collaborative arrangements

744

689

1,458

1,277

Cost

of sales (c)

(35

(36

(91

(67

Selling,

informational and administrative expenses(d)

14

26

(3

19

Research

and development expenses(e)

(50

(46

(244

(96

(a)

Represents

sales to our partners of products manufactured by

us.

(b)

Substantially

all related to amounts earned from our partners under co-promotion

agreements.

(c)

Primarily

related to royalties earned by our partners and cost of sales associated

with inventory purchased from our

partners.

(d)

Represents

net reimbursements from our partners and reimbursements to our partners

for Selling, informational and administrative expenses

incurred.

(e)

Primarily

related to net reimbursements earned by our partners, except that the

first quarter of 2009 also includes a $150 million milestone payment to

one of our partners.

The

amounts disclosed in the above table do not include transactions with third

parties other than our collaboration partners, or other costs associated with

the products under the collaboration arrangements.

PFIZER

INC. AND SUBSIDIARY COMPANIES

NOTES TO

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 5. Cost-Reduction

Initiatives

We

incurred the following costs in connection with all of our cost-reduction

initiatives, which began in 2005:

Three

Months Ended

Six

Months Ended

(millions

of dollars)

June

28,

2009

June

29,

2008

June

28,

2009

June

29,

2008

Implementation

costs(a)

156

405

330

762

Restructuring

charges(b)

174

562

331

739

Total

costs related to our cost-reduction initiatives

330

967

661

1,501

(a)

For

the second quarter of 2009, included in Cost of sales ($45

million), Selling,

informational and administrative expenses ($85 million), Research and development

expenses ($32 million), and Other (income)/deductions -

net ($6 million income). For the second quarter of 2008, included

in Cost of sales

($210 million), Selling,

informational and administrative expenses ($100 million), Research and development

expenses ($94 million) and Other (income)/deductions -

net ($1 million). For the first six months of 2009, included in

Cost of sales

($121 million), Selling,

informational and administrative expenses ($131 million), Research and development

expenses ($73 million), and Other (income)/deductions -

net ($5 million). For the first six months of 2008, included in

Cost of sales

($348 million), Selling,

informational and administrative expenses ($175 million), Research and development

expenses ($240 million) and Other (income)/deductions -

net ($1 million

income).

(b)

Included

in Restructuring charges

and acquisition-related

costs.

From the

beginning of the cost-reduction initiatives in 2005 through June 28, 2009, the

restructuring charges primarily relate to our supply network transformation

efforts and the restructuring of our worldwide marketing and research and

development operations, and the implementation costs primarily relate to

depreciation arising from the shortening of the useful lives of certain assets,

as well as system and process standardization and the expansion of shared

services.

The

components of restructuring charges associated with all of our cost-reduction

initiatives follow:

(millions

of dollars)

Costs

Incurred

Through

June

28, 2009

Activity

Through

June

28, 2009(a)

Accrual

as of

June

28, 2009(b)

Employee

termination costs

5,314

3,947

1,367

Asset

impairments

1,384

1,384

Other

516

420

96

Total

restructuring charges

7,214

5,751

1,463

(a)

Includes

adjustments for foreign currency

translation.

(b)

Included

in Other current

liabilities ($954 million) and Other noncurrent liabilities

($509 million).

During

the second quarter of 2009, we expensed $29 million for Employee termination costs,

$73 million for Asset

impairments and $72 million for Other. During the first six

months of 2009, we expensed $164 million for Employee termination costs,

$91 million for Asset

impairments and $76 million for Other. From June 2005 through

June 28, 2009, Employee

termination costs, net of the impact of a change in estimate, represent the expected

reduction of the workforce by approximately 31,100 employees, mainly in

manufacturing, sales and research, and approximately 25,500 of these employees

have been terminated. Employee

termination costs are recorded when the actions are probable and

estimable and include accrued severance benefits, pension and postretirement

benefits. Asset

impairments primarily include charges to write down property, plant and

equipment. Other

primarily includes costs to exit certain activities.

PFIZER

INC. AND SUBSIDIARY COMPANIES

NOTES TO

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 6. Acquisition-Related

Costs

We

incurred the following acquisition-related costs primarily in connection with

our pending acquisition of Wyeth:

Three

Months Ended

Six

Months Ended

(millions

of dollars)

June

28,

2009

June

29,

2008

June

28,

2009

June

29,

2008

Transaction

costs (a)

184

553

Pre-integration

costs and other(b)

101

129

Total

acquisition-related costs(c)

285

682

(a)

Transaction

costs include banking, legal, accounting and other costs directly related

to our pending acquisition of Wyeth. Substantially all of the costs

incurred to date are fees related to a $22.5 billion bridge term loan

credit agreement entered into with certain financial institutions on March

12, 2009, to partially fund our pending acquisition of Wyeth. The bridge

term loan credit agreement was terminated in June 2009 as a result of our

issuance of approximately $24.0 billion of senior unsecured notes during

the first six months of 2009. All bridge term loan commitment fees have

been expensed, and we are no longer subject to the covenants under that

agreement (see Note 8D:

Financial Instruments: Long-Term

Debt).

(b)

Pre-integration

costs and other primarily represent external, incremental costs of

integration planning that are directly related to our pending acquisition

of Wyeth and include costs associated with preparing for systems and other

integration activities.

(c)

Included

in Restructuring charges

and acquisition-related

costs.

Note 7. Comprehensive

Income/(Expense)

The

components of comprehensive income/(expense) follow:

Three

Months Ended

Six

Months Ended

(millions

of dollars)

June

28,

2009

June

29,

2008

June

28,

2009

June

29,

2008

Net

income before allocation to noncontrolling interests

2,266

2,782

4,996

5,572

Other

comprehensive expense:

Currency translation adjustment

and other

2,638

1,109

2,254

534

Net unrealized gains/(losses)

on derivative financial instruments

(144

27

(167

28

Net unrealized gains/(losses)

on available-for-sale securities

81

226

(14

Benefit plan

adjustments

18

177

85

Total other comprehensive

loss

2,593

1,137

2,490

633

Total

comprehensive income before allocation to

noncontrolling

interests

4,859

3,919

7,486

6,205

Less: Comprehensive income

attributable to

noncontrolling

interests

12

15

14

23

Comprehensive

income attributable to Pfizer Inc.

4,847

3,904

7,472

6,182

10

PFIZER

INC. AND SUBSIDIARY COMPANIES

NOTES TO

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 8. Financial

Instruments

A. Selected Financial Assets

and Liabilities

Information

about certain of our financial assets and liabilities follows:

(millions

of dollars)

June

28,

2009

Dec.

31,

2008

Selected

financial assets measured at fair value on a recurring basis (a)

Trading securities (b)

172

190

Available-for-sale debt securities

(c)

50,592

30,061

Available-for-sale money market

funds

7,543

398

Available-for-sale equity

securities, excluding money market funds (c)

182

319

Derivative financial instruments

in receivable positions (d)

Interest rate

swaps

283

732

Foreign currency

swaps

85

128

Foreign currency forward-exchange

contracts

640

399

Total

59,497

32,227

Other

selected financial assets (e):

Held-to-maturity debt

securities, carried at amortized cost (c)

953

2,349

Short-term loans, carried at

cost

935

824

Long-term loans, carried at

cost

1,181

1,568

Private equity securities,

carried at cost

168

182

Total

3,237

4,923

Total

selected financial assets

62,734

37,150

Financial

liabilities measured at fair value on a recurring basis (a):

Derivative financial instruments

in a liability position (f):

Interest rate

swaps

Foreign currency

swaps

352

153

Foreign currency forward-exchange

contracts

1,381

1,083

Total

1,741

1,243

Other

financial liabilities (e) ,

(g):

Short-term borrowings, carried at

historical proceeds, as adjusted (h)

7,645

9,320

Long-term debt, carried at

historical proceeds, as adjusted (i)

31,864

7,963

Total

39,509

17,283

Total

selected financial liabilities

41,250

18,526

(a)

Fair

values are determined based on valuation techniques categorized as

follows: Level 1 means the use of quoted prices for identical instruments

in active markets; Level 2 means the use of quoted prices for similar

instruments in active markets or quoted prices for identical or similar

instruments in markets that are not active or are directly or indirectly

observable; Level 3 means the use of unobservable inputs. Virtually all of

our financial assets and liabilities measured at fair value on a recurring

basis use Level 2 inputs in the calculation of fair value, except that

included in available-for-sale equity securities, excluding money market

funds, are $101 million as of June 28, 2009 and $87 million as of December

31, 2008 of investments that use Level 1 inputs in the calculation of fair

value. None of our financial assets and liabilities measured at fair value

on a recurring basis are valued based on Level 3 inputs at June 28, 2009

or December 31, 2008.

(b)

Trading

securities are held in trust for legacy Pharmacia severance

benefits.

(c)

Gross

unrealized gains and losses are not

significant.

(d)

Designated

as hedging instruments except for certain foreign currency contracts used

as offsets, namely, foreign currency forward-exchange contracts with fair

values of $6 million and foreign currency swaps with fair values of $77

million at June 28, 2009; and foreign currency forward-exchange contracts

with fair values of $175 million and foreign currency swaps with fair

values of $32 million at December 31,

2008.

(e)

The

differences between the estimated fair values and carrying values of our

financial assets and liabilities not measured at fair value on a recurring

basis were not significant as of June 28, 2009 or December 31,

2008.

(f)

Designated

as hedging instruments except for certain foreign currency contracts used

as offsets, namely, foreign currency forward-exchange contracts with fair

values of $515 million and foreign currency swaps with

fair values of $32 million at June 28, 2009; and foreign currency

forward-exchange contracts with fair values of $836 million and foreign

currency swaps with fair values of $76 million at December 31,

2008.

(g)

The

carrying amounts may include adjustments for discount or premium

amortization or for the effect of interest rate swaps designated as

hedges.

(h)

Includes

foreign currency borrowings with fair values of $1.0 billion at June 28,

2009 and $1.6 billion at December 31, 2008, which are used as hedging

instruments.

(i)

Includes

foreign currency debt with fair values of $2.0 billion at June 28, 2009

and $2.1 billion at December 31, 2008, which is used as a hedging

instrument.

11

PFIZER

INC. AND SUBSIDIARY COMPANIES

NOTES TO

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The

following methods and assumptions were used to estimate the fair value of our

financial assets and liabilities:

Trading

equity securities - quoted market

prices.

Trading debt securities

- observable market interest

rates.

Available-for-sale

debt securities - matrix-pricing model using observable market quotes and

credit ratings.

Available-for-sale

money market funds - observable

prices.

Available-for-sale

equity securities, excluding money market funds - pricing services that